The CANabidiol Use for RElief of Short Term Insomnia

Insomnia Clinical Trial

— CANREST  

Official title:

The CANabidiol Use for RElief of Short Term Insomnia (CAN-REST). A Randomised, Double-Blind, Placebo-Controlled Clinical Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05253417
• Other study ID #: BOD202101
• Status: Completed
• Phase: Phase 2
• Start date: May 1, 2022
• Est. completion date: July 7, 2023

Study information

• Verified date: August 2023
• Source: Bod Australia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.

Description:

This is a double-blind, randomised, parallel-group, placebo-controlled study of 8 weeks of oral CBD at 50 or 100 mg per day versus placebo in 198 participants with insomnia symptoms as classified by an Insomnia Severity Index (ISI) score of 8-21. Participants will be recruited voluntarily and are able to withdraw at any time. The study will be conducted online with telehealth consults where required.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 208
• Est. completion date: July 7, 2023
• Est. primary completion date: July 7, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male and females aged 18-65 years old, inclusive.

2. Females must be non-pregnant, non-lactating.

3. Proficient in English and have internet access and a mobile phone.

4. Insomnia symptoms as classified by an Insomnia Severity Index (ISI) score of 8 - 21 and have experienced these symptoms over the past month at pre-screening.

5. Stated willingness to comply with all study procedures and availability for the duration of the study.

6. Provision of signed and dated informed consent form.

7. All male and females of childbearing potential must agree to use two forms of effective contraception from the time of signing informed consent until 30 days after study completion.

Exclusion Criteria:

1. Serious medical and/or psychiatric illnesses/disorders that will require treatment during the trial period.

2. The use of any drug known to affect sleep during the study one week prior the

randomization, including:

1. Sedatives (benzodiazepines, Z drugs, agomelatine, suvorexant, sodium oxybate, sedating antidepressants, sedating antihistamines, antipsychotics, melatonin, valerian).

2. Opioids (e.g. morphine, codeine, oxycodone, methadone, buprenorphine, fentanyl, tramadol, tapentadol, hydromorphone).

3. Stimulants (e.g. methylphenidate, dexamphetamine, modafinil, phentermine).

3. Excessive caffeine use (defined as > 600mg caffeine or approximately 6 cups of caffeinated beverages a day) that, in the opinion of the medical doctor, contributes to the participant's insomnia.

4. Excessive alcohol use (defined as per NHMRC guideline, i.e. no more than four standard drinks per day on average for men, and for women, no more than two).

5. The use of cannabinoids or a cannabinoid-based medicine within 3 months prior to study Day 1 and unwillingness to abstain from recreational drug use during the study period.

6. Cannabis dependence or any other drug or alcohol dependence within the past two years.

7. Positive urine drug screen (e.g., amphetamines type substances, benzodiazepines, cannabinoids, cocaine, and opiates) at screening or Day -1 or a history of drug abuse within the past 2 years.

8. Known hypersensitivity to cannabis-based products or any of the excipients in the study drug.

9. Use of any investigational drug or involvement in another clinical trial within 30 days of screening day.

10. Use of anti-coagulant drugs such as warfarin or those known to be metabolised by CYP450 enzymes.

11. Current or ongoing treatments for insomnia (e.g. cognitive-behavioural therapy (CBT) and CNS-active drugs).

12. Obstructive sleep apnoea determined by the MAPI questionnaire or other self-reported sleep disorders.

13. Medical conditions that result in frequent sleep disturbance (e.g. nocturia).

14. History of attempted suicide in the past 12 months.

15. Clinically significant hepatic abnormalities determined by the screening blood test.

16. Shift work, jet lag or trans-meridian travel (two time zones) in the past month.

Related Conditions & MeSH terms

• Dyssomnias
• Insomnia
• Insomnia Due to Anxiety and Fear
• Insomnia Due to Other Mental Disorder
• Insomnia Type; Sleep Disorder
• Mental Disorders
• Parasomnias
• Sleep Disturbance
• Sleep Initiation and Maintenance Disorders
• Sleep Wake Disorders

Intervention

Drug:
• 50 mg Cannabidiol (CBD)
For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
• Placebo
Participants take four (4) placebo capsules.
• 100 mg Cannabidiol (CBD)
For the study arm, '100 mg CBD' participants take four (4) CBD capsules.

Locations

Country	Name	City	State
Australia	Fusion Clinical Research	Adelaide	South Australia
Australia	Woolcock Institute	Glebe	New South Wales

Sponsors (2)

Lead Sponsor	Collaborator
Bod Australia	Woolcock Institute of Medical Research

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Sleep onset latency (SOL) measured by actigraphy.	Sleep onset latency (SOL) is the time it takes to transition from wakefulness to non-REM sleep. On average, the SOL should take between 10-20 minutes. Short sleep latencies usually reflect increased sleepiness.	Baseline (week 0), week 8
Other	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on subjective sleep as assessed by sleep diaries	Participants will be requested to complete a short, 5-minute online sleep diary for seven mornings to describe the previous night's sleep at baseline, week 4 and week 8.	Baseline (week 0), week 4, week 8
Other	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on self-perception of improvement in sleep as assessed by a self-report questionnaire.	The self-report questionnaire will ask participants to rate their self-perceived improvement in sleep using a standard 10-point visual analogue scale at weeks 4 and 8	Baseline (week 0), week 4, week 8
Other	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Subjective sleep-related quality of life as assessed by the Functional Outcomes Sleep Questionnaire (FOSQ-10).	FOSQ-10 is a 10 items questionnaire to measure the impact of daytime sleepiness on activities of daily living. The score range is 5-20 points, with higher scores indicating better functional status.	Baseline (week 0), week 4, week 8
Other	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Fatigue assessed by the Flinders Fatigue Scale;	The Flinders Fatigue Scale is a 7 items self-report scale which assess fatigue over the past 2 weeks. This scale provides a total fatigue score ranging from 0 to 31, with higher scores indicating greater fatigue.	Baseline (week 0), week 4, week 8
Other	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Health-related quality of life (HRQoL) assessed using the EQ-5D-5L.	A descriptive system for health-related quality of life states in adults, consisting of five dimensions. Each of which has five severity levels that are described by statements appropriate to that dimension. Those are rated by a verbal 5-point rating scale allowing for distinction of five levels ('5L') of severity: Level 1: no problems; Level 2: slight problems; Level 3: moderate problems; Level 4: severe problems; Level 5: extreme problems per dimension and providing a 1-digit number for each dimension.	Baseline (week 0), week 4, week 8
Other	To determine the effect of 8 weeks of 50mg or 100mg of CBD on the number of participants with treatment-emergent adverse events	The safety and tolerability of the investigational product will be determined by evaluating all incidences of treatment-emergent adverse events as assessed by reported by participants or observed by the investigators or from the safety pathology tests.	Week 4, Week 8, Week 12
Other	To determine relationship between efficacy endpoint and systemic concentrations of CBD and its carboxy and hydroxy metabolites	Systemic concentrations of CBD (ng/mL), 7- hydroxycannabidiol (7-OH-CBD) (ng/mL) and 7- carboxycannabidiol (7- COOH-CBD) (ng/mL) will be analysed in plasma and urine samples collected at baseline and week 8.	Baseline (week 0), week 8
Other	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Depression as assessed by the DASS-21 questionnaire.	Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately. Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).	Baseline (week 0), Week 4, week 8
Primary	To investigate the effect of the administration of a 50mg and 100mg per day oral CBD product versus placebo over 8 weeks on insomnia severity index scores	Insomnia Severity Index (ISI): A 7-item tool measuring the nature, severity, and impact of insomnia over the past 2 weeks. Each item uses a 5-point Likert scale to capture a rating (0 = no problem; 4 = very severe problem) which add up to: no insomnia (0 - 7); sub-threshold insomnia (8 - 14); moderate insomnia (15 - 21); and severe insomnia (22 - 28).	Baseline (week 0), week 4, week 8
Secondary	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on wake after sleep onset (WASO) as assessed by actigraphy.	WASO is a parameter that examines the total amount of minutes awake after the first sleep epoch is achieved. Therefore, as the WASO increases, sleep efficiency decreases.	Baseline (week 0), week 8
Secondary	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Anxiety as assessed by the DASS-21 questionnaire.	Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately. Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).	Baseline (week 0), Week 4, week 8
Secondary	To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Stress as assessed by the DASS-21 questionnaire.	Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately. Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).	Baseline (week 0), Week 4, week 8

External Links

•   Information for Patients